Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 199

1.

Overcoming persistent dependency on androgen signaling after progression to castration-resistant prostate cancer.

Yamaoka M, Hara T, Kusaka M.

Clin Cancer Res. 2010 Sep 1;16(17):4319-24. doi: 10.1158/1078-0432.CCR-10-0255. Epub 2010 Jul 20. Review.

2.

Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors.

Cai C, Chen S, Ng P, Bubley GJ, Nelson PS, Mostaghel EA, Marck B, Matsumoto AM, Simon NI, Wang H, Chen S, Balk SP.

Cancer Res. 2011 Oct 15;71(20):6503-13. doi: 10.1158/0008-5472.CAN-11-0532. Epub 2011 Aug 25.

3.

The evolving paradigm of second-line hormonal therapy options for castration-resistant prostate cancer.

Courtney KD, Taplin ME.

Curr Opin Oncol. 2012 May;24(3):272-7. doi: 10.1097/CCO.0b013e328351059d. Review.

PMID:
22327837
4.

Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer.

Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA, Ettinger SL, Gleave ME, Nelson CC.

Cancer Res. 2008 Aug 1;68(15):6407-15. doi: 10.1158/0008-5472.CAN-07-5997.

5.

Changing therapeutic paradigms in castrate-resistant prostate cancer.

Zivi A, Massard C, De-Bono J.

Clin Genitourin Cancer. 2010 Dec 1;8(1):17-22. doi: 10.3816/CGC.2010.n.003. Review.

PMID:
21208851
6.

Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model.

Leon CG, Locke JA, Adomat HH, Etinger SL, Twiddy AL, Neumann RD, Nelson CC, Guns ES, Wasan KM.

Prostate. 2010 Mar 1;70(4):390-400. doi: 10.1002/pros.21072.

PMID:
19866465
7.

"Getting from here to there"--mechanisms and limitations to the activation of the androgen receptor in castration-resistant prostate cancer.

Sharifi N, McPhaul MJ, Auchus RJ.

J Investig Med. 2010 Dec;58(8):938-44. doi: 10.231/JIM.0b013e3181ff6bb8. Review.

PMID:
21030877
8.

Abiraterone acetate, a novel adrenal inhibitor in metastatic castration-resistant prostate cancer.

Salem M, Garcia JA.

Curr Oncol Rep. 2011 Apr;13(2):92-6. doi: 10.1007/s11912-011-0153-4. Review.

PMID:
21243537
9.

Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.

Vis AN, Schröder FH.

BJU Int. 2009 Aug;104(4):438-48. doi: 10.1111/j.1464-410X.2009.08695.x. Epub 2009 Jun 24. Review.

10.

Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer.

Rehman Y, Rosenberg JE.

Drug Des Devel Ther. 2012;6:13-8. doi: 10.2147/DDDT.S15850. Epub 2012 Jan 16. Review.

11.

Oxidative stress and androgen receptor signaling in the development and progression of castration-resistant prostate cancer.

Shiota M, Yokomizo A, Naito S.

Free Radic Biol Med. 2011 Oct 1;51(7):1320-8. doi: 10.1016/j.freeradbiomed.2011.07.011. Epub 2011 Jul 23. Review.

PMID:
21820046
12.

Abiraterone acetate for castration resistant prostate cancer.

Shah S, Ryan C.

Expert Opin Investig Drugs. 2010 Apr;19(4):563-70. doi: 10.1517/13543781003639427. Review.

PMID:
20225998
13.

Targeting continued androgen receptor signaling in prostate cancer.

Massard C, Fizazi K.

Clin Cancer Res. 2011 Jun 15;17(12):3876-83. doi: 10.1158/1078-0432.CCR-10-2815. Review.

14.

New agents and strategies for the hormonal treatment of castration-resistant prostate cancer.

Sharifi N.

Expert Opin Investig Drugs. 2010 Jul;19(7):837-46. doi: 10.1517/13543784.2010.494178. Review.

PMID:
20524793
15.

Androgen receptor: role and novel therapeutic prospects in prostate cancer.

Taplin ME.

Expert Rev Anticancer Ther. 2008 Sep;8(9):1495-508. doi: 10.1586/14737140.8.9.1495. Review.

PMID:
18759700
16.

Cholesterol as a potential target for castration-resistant prostate cancer.

Twiddy AL, Leon CG, Wasan KM.

Pharm Res. 2011 Mar;28(3):423-37. doi: 10.1007/s11095-010-0210-y. Epub 2010 Aug 4. Review.

PMID:
20683646
17.

Beyond castration-defining future directions in the hormonal treatment of prostate cancer.

Niraula S, Chi K, Joshua AM.

Horm Cancer. 2012 Apr;3(1-2):3-13. doi: 10.1007/s12672-011-0096-0. Review.

PMID:
22124843
18.

Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy.

Cai C, Balk SP.

Endocr Relat Cancer. 2011 Aug 30;18(5):R175-82. doi: 10.1530/ERC-10-0339. Print 2011 Oct. Review.

19.

P450-dependent enzymes as targets for prostate cancer therapy.

De Coster R, Wouters W, Bruynseels J.

J Steroid Biochem Mol Biol. 1996 Jan;56(1-6 Spec No):133-43. Review.

PMID:
8603034
20.

Arachidonic acid activation of intratumoral steroid synthesis during prostate cancer progression to castration resistance.

Locke JA, Guns ES, Lehman ML, Ettinger S, Zoubeidi A, Lubik A, Margiotti K, Fazli L, Adomat H, Wasan KM, Gleave ME, Nelson CC.

Prostate. 2010 Feb 15;70(3):239-51. doi: 10.1002/pros.21057.

PMID:
19790237
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk